Pomalidomide
- Generic Name
- Pomalidomide
- Brand Names
- Imnovid, Pomalyst, Imnovid (previously Pomalidomide Celgene), Pomalidomide Viatris, Pomalidomide Zentiva, Pomalidomide Krka, Pomalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C13H11N3O4
- CAS Number
- 19171-19-8
- Unique Ingredient Identifier
- D2UX06XLB5
- Background
Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
- Indication
Pomalidomide is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and have demonstrated disease progression on or within 60 days of completion of the last therapy. It is also indicated for the treatment of Kaposi's sarcoma (KS) in AIDS patients who have failed highly active antiretroviral thera...
- Associated Conditions
- Kaposi's Sarcoma, Multiple Myeloma (MM)
- Associated Therapies
- -
To Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2024-12-19
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 284
- Registration Number
- NCT06742138
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-refractory Multiple Myeloma (QUINTESSENTIAL-2)
- Conditions
- Interventions
- First Posted Date
- 2024-09-26
- Last Posted Date
- 2024-12-20
- Target Recruit Count
- 440
- Registration Number
- NCT06615479
- Locations
- 🇦🇺
Local Institution - 0190, Liverpool, New South Wales, Australia
🇦🇺Local Institution - 0191, Melbourne, Victoria, Australia
🇺🇸Local Institution - 0071, Birmingham, Alabama, United States
A Study of Pomadomide in Combination With Rituximab and Methotrexate for Newly-diagnosed Primary Central Nervous System Lymphoma
- First Posted Date
- 2024-08-15
- Last Posted Date
- 2024-08-15
- Target Recruit Count
- 43
- Registration Number
- NCT06554561
- Locations
- 🇨🇳
2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hanzhou, Zhejiang, China
A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients
- Conditions
- Interventions
- First Posted Date
- 2024-07-19
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Hangzhou Sumgen Biotech Co., Ltd.
- Target Recruit Count
- 360
- Registration Number
- NCT06508983
- Locations
- 🇨🇳
Guangzhou First People's Hospital, Guangzhou, Guangdong, China
🇨🇳Beijing Chaoyang Hospital of Capital Medical University, Beijing, Beijing, China
🇨🇳First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China
A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
- Conditions
- Interventions
- First Posted Date
- 2024-06-18
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Nanjing IASO Biotechnology Co., Ltd.
- Target Recruit Count
- 240
- Registration Number
- NCT06464991
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, China
🇨🇳Peking University Third Hospital, Beijing, China
🇨🇳People's Hospital of Peking University, Beijing, China
Daratumumab/Daratumumab and Hyaluronidase-fihj in Combination With Pomalidomide and Dexamethasone for the Treatment of Patients With Newly Diagnosed AL Amyloidosis: a Prospective, Multicenter, Single-arm Study
- Conditions
- Interventions
- First Posted Date
- 2024-06-12
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- Yongyong MA
- Target Recruit Count
- 20
- Registration Number
- NCT06455748
- Locations
- 🇨🇳
The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
- First Posted Date
- 2024-05-14
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 450
- Registration Number
- NCT06413498
- Locations
- 🇺🇸
UCLA Department of Medicine-Hematology/Oncology, Santa Monica, California, United States
🇺🇸Baptist Cancer Center, Memphis, Tennessee, United States
🇦🇺Epworth HealthCare, Richmond, Victoria, Australia
Bortezomib, Pomalidomide, Dexamethasone For Systemic AL Amyloidosis
- Conditions
- Interventions
- First Posted Date
- 2024-04-02
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Jin Lu, MD
- Target Recruit Count
- 40
- Registration Number
- NCT06342466
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- Conditions
- Interventions
- First Posted Date
- 2024-01-31
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- Celgene
- Registration Number
- NCT06232707
- Locations
- 🇺🇸
Local Institution - 0088, Los Angeles, California, United States
🇺🇸Local Institution - 0324, Baltimore, Maryland, United States
🇦🇺Local Institution - 0022, Waratah, New South Wales, Australia
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
- Conditions
- Interventions
- First Posted Date
- 2024-01-17
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 795
- Registration Number
- NCT06208150
- Locations
- 🇨🇳
The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
🇨🇳Tongji Hospital, Tongji Medical College of HUST, Wuhan, China
🇮🇱Carmel Medical Center, Haifa, Israel
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.